CHANNEL THERAPEUTICS CORP(NYSEARCA:CHRO) stock News

CHRO Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Benzinga - Mentions: LGND PTHS

Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease

3 months ago - By: Channel Therapeutics Corporation - Mentions: PTHS

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

3 months ago - By: Benzinga

Why Is Channel Therapeutics Stock Surging On Friday?

3 months ago - By: Channel Therapeutics Corporation

Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

a year ago - By: InvestorPlace

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024

a year ago - By: InvestorPlace

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024

5 months ago - By: Channel Therapeutics Corporation

Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules

5 months ago - By: Stocktwits - Mentions: LGND IJR

Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated

5 months ago - By: Yahoo Finance - Mentions: LGND NVDA AAPL

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

9 months ago - By: Channel Therapeutics Corporation

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

9 months ago - By: Channel Therapeutics Corporation

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

10 months ago - By: Channel Therapeutics Corporation

Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates

a year ago - By: Chromocell Therapeutics Corporation

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

a year ago - By: Chromocell Therapeutics Corporation

Chromocell to Present at Upcoming Fall Investor Conferences

a year ago - By: Chromocell Therapeutics Corporation

Chromocell Announces Amendment to Stock Repurchase Plan

a year ago - By: Virtual Investor Conferences - Mentions: VNRX APRE PLX ACST ...

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

a year ago - By: Chromocell Therapeutics Corporation

Chromocell Announces Stock Repurchase Plan

a year ago - By: Chromocell Corporation

Chromocell to Participate in the Virtual Investor Lunch Break Series

a year ago - By: Chromocell Corporation

CHANNEL THERAPEUTICS CORP (CHRO) Stock News

CHRO Latest News, Press Relases and Analysis

Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

Why Is Channel Therapeutics Stock Surging On Friday?

Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024

Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules

Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine

Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model

Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

Chromocell to Present at Upcoming Fall Investor Conferences

Chromocell Announces Amendment to Stock Repurchase Plan

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Chromocell Announces Stock Repurchase Plan

Chromocell to Participate in the Virtual Investor Lunch Break Series

Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024